Eli Lilly announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company to expand its infectious disease research. These acquisitions focus on developing vaccines targeting viral and bacterial pathogens linked to long-term health risks like neurological diseases, cancer, and antibiotic-resistant infections. Lilly aims to enhance prevention strategies, including a better-tolerated shingles vaccine and vaccines against bacterial infections and Epstein-Barr Virus. The deals include milestone-based payments totaling up to $3.83 billion and are subject to regulatory approval.
Lilly has agreed to acquire Curevo Vaccine, a biotech firm developing a next-generation shingles vaccine called amezosvatein, designed to improve tolerability and increase vaccination rates. The deal could pay Curevo shareholders up to $1.5 billion, ...
Eli Lilly reported positive Phase 1b results for VERVE-102, a gene therapy that permanently silences the PCSK9 gene to reduce LDL cholesterol by up to 62%. The therapy showed sustained effects for up to 18 months and was well-tolerated with no seriou...
Eli Lilly reported Phase III data for its weight loss drug retatrutide showing strong dose-dependent efficacy, with up to 30% weight loss at 104 weeks in patients with BMI over 35. UBS analysts highlight the drug's potential to differentiate itself i...
The Vanguard Dividend Appreciation Index Fund ETF (VIG) has posted a modest 5% gain year-to-date, underperforming the broader market due to rising long-term Treasury yields, which compete with dividend yields. While dividend growth continues, investo...
Eli Lilly's Phase 1b Heart-2 trial showed that a single intravenous dose of VERVE-102 significantly lowered PCSK9 protein and LDL cholesterol (LDL-C) in patients at high risk for cardiovascular disease, with reductions lasting up to 18 months. The tr...
